Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 26

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 26
---
 presentation led to several follow-on
meetings, and we have recently agreed to service agreements in the areas of business development, CMC (Chemistry, Manufacturing, and
Controls), regulatory affairs and clinical trial management. The Asian market is very large and hard to penetrate for a small company
and we believe that our strategy with these agreements is cost effective and have the possibility to accelerate an out-licensing deal
in the South-East Asian territories. However, there are no assurances that this approach will be successful.

The
agreements executed are very similar in nature that include an equity investment in our Company by the other party and in turn we issued
equity in the form of shares of common stock, in lieu of cash, for 3 years of services from each company.

The
Company believes these agreements to be favorable for both parties based on the cash position of the Company and the need for these activities
to be executed and enabling the possibility of a one or more out-licensing agreements in the territory.

27

Contractual
Obligations

We
do not have any long-term capital lease obligations, operating lease obligations or long-term liabilities, except as follows:

Notes
Payable to Related Parties and Other Transactions

The
Company’s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to the
CEO as of June 30, 2025 and December 31, 2024 and 2023 was $146,432, respectively. The loan is due on demand and accrues interest at
3% per year. Accrued interest relating to the loan was $3,242 and $1,064 as of June 30, 2025 and December 31, 2024, respectively, and
is included in accrued interest on the accompanying balance sheets.

As
of June 30, 2025 and December 31, 2024, $85,466 and $64,105, respectively, was due to a company wholly owned by the Company’s Chief
Financial Officer. The amount is included in accrued compensation on the Company’s balance sheets.

Critical
Accounting Policies

Our
accounting policies are more fully described in Note 2 – Significant accounting policies to our consolidated financial statements
included as part of this Quarterly Report and our 2024 Annual Report on Form 10-K, filed with the SEC on March 28, 2025.

28

ITEM
3. QUANTITATIVE AND QUAL